December 4, 2018 07:06 AM EST

Vanda's PhII data offer hope for gastroparesis patients who have seen no new treatments in decades

ENDPOINTS

As one of the handful of drugs-in-development for gastroparesis, Vanda Pharmaceuticals’ $VNDA tradipitant has set itself apart for the condition that affects about 6 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Vanda's PhII data offer hope for gastroparesis patients who have seen no new treatments in decades

ENDPOINTS

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

The ‘MAHA report’: Four key takeaways on vaccines, medicine and the pharma industry

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

FDA chief to senators: 3,000+ staff departures won't delay user fee targets

House passes Trump tax bill with PBM and orphan drug reforms included

Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Van­da's PhII da­ta of­fer hope for gas­tro­pare­sis pa­tients who have seen no new treat­ments in decades

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Vanda's PhII data offer hope for gastroparesis patients who have seen no new treatments in decades